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Abstract
Influenza viruses isolated during the 2009 H1N1 pandemic generally lack known molecular determinants of virulence
associated with previous pandemic and highly pathogenic avian influenza viruses. The frequency of the amino acid
substitution D222G in the hemagglutinin (HA) of 2009 H1N1 viruses isolated from severe but not mild human cases
represents the first molecular marker associated with enhanced disease. To assess the relative contribution of this
substitution in virus pathogenesis, transmission, and tropism, we introduced D222G by reverse genetics in the wild-type HA
of the 2009 H1N1 virus, A/California/04/09 (CA/04). A dose-dependent glycan array analysis with the D222G virus showed a
modest reduction in the binding avidity to human-like (a2-6 sialylated glycan) receptors and an increase in the binding to
avian-like (a2-3 sialylated glycan) receptors in comparison with wild-type virus. In the ferret pathogenesis model, the D222G
mutant virus was found to be similar to wild-type CA/04 virus with respect to lethargy, weight loss and replication efficiency
in the upper and lower respiratory tract. Moreover, based on viral detection, the respiratory droplet transmission properties
of these two viruses were found to be similar. The D222G virus failed to productively infect mice inoculated by the ocular
route, but exhibited greater viral replication and weight loss than wild-type CA/04 virus in mice inoculated by the intranasal
route. In a more relevant human cell model, D222G virus replicated with delayed kinetics compared with wild-type virus but
to higher titer in human bronchial epithelial cells. These findings suggest that although the D222G mutation does not
influence virus transmission, it may be considered a molecular marker for enhanced replication in certain cell types.
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Introduction
The 2009 H1N1 pandemic influenza virus spread from its first
detection in humans in March 2009 to all populated continents in
a matter of weeks, causing over 18,000 laboratory-confirmed
deaths reported to WHO in over 215 countries [1]. Although the
WHO assessed the impact of the H1N1 pandemic as moderate
since the majority of infected patients experienced mild influenza-
like illness (www.who.int), the 2009 H1N1 virus caused a wide
spectrum of influenza-related complications in children less than 5
years of age, pregnant women, and those with certain underlying
comorbidities [2,3,4,5]. Although preexisting immune status and
underlying chronic medical conditions are recognized risk factors
for severe disease, the viral molecular determinants governing
virulence of the 2009 H1N1 virus are poorly understood.
Previous studies on highly pathogenic influenza viruses have
contributed to the identification of numerous molecular markers
associated with adaptation to human hosts and increased virulence
and transmissibility, including key amino acids at the 627 and 701
positions in PB2 and the presence of full-length PB1-F2 and NS1
proteins [6,7,8,9]. However, the analysis of 2009 H1N1 viruses
revealed an absence of these known molecular determinants,
underscoring the virus-specific nature of such determinants and
the existence of as yet unrecognized molecular features that
contributed to the establishment of the 2009 H1N1 virus as a
pandemic strain with moderate virulence [10]. A potential
virulence marker associated with 2009 H1N1 viruses was first
identified among patients in Norway, with a change from aspartic
acid to glycine at position 222 (D222G) in HA1 present in 18% of
clinical specimens from patients with severe disease but in 0% of
those from mild cases [11]. Subsequent reports from cases
worldwide further strengthened this association [12,13,14,15,
16,17]. These retrospective analyses have found that cases bearing
the D222G mutation were more likely to be associated with severe
pneumonia, admission to intensive care facilities, and death [18].
Several studies in in vitro and in vivo models have examined the role
of D222G in 2009 H1N1 virus virulence with varying outcomes.
The majority of studies have reported that presence of D222G is
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sufficient to enhance virus replication and lethality in mouse
models, with this effect ranging from modest to pronounced
[19,20,21]. However, other groups have not observed substantial
differences between wild-type and D222G viruses in mouse or
ferret models [22], indicating the need for further investigation
into the role of D222G in virulence of 2009 H1N1 pandemic
viruses.
The location of position 222 in the receptor binding site of HA
predicts that alteration of this position would influence the binding
specificity of a virus bearing this mutation [23]. Recent studies
have reported that the D222G mutation confers enhanced binding
to a2-3 linked sialic acids, suggesting a greater ability to bind to
lung cells in the lower respiratory tract in humans and cause an
exacerbation of disease [22,24]. In the present study, a 2009
H1N1 virus A/California/04/09 (CA/04) was mutated to gen-
erate the HA D222G mutation in order to study the role of
D222G in pathogenesis and transmission in both ferret and mouse
models. A dose-dependent direct binding glycan array analysis of
virus carrying the D222G HA mutation showed observable
changes in binding to glycans terminated by both a2-6 and a2-
3-linked sialic acids. Although the presence of this mutation did
not cause a significant increase in pathogenesis and transmission in
ferrets, it caused heightened virulence of this virus in mice and
exhibited enhanced replication in human respiratory cells in
comparison to the wild-type CA/04 virus.
Results
Effect of D222G mutation on the receptor binding
properties of HA
Asp222 in the wild-type CA/04 HA is a characteristic residue
predominantly found in human-adapted H1N1 viruses. This
residue has been shown to play a key role in providing optimal
contacts with the penultimate Gal sugar in glycans terminated by
a2-6-linked sialic acid [25,26]. Therefore a D222G mutation is
likely to affect the molecular contacts of this key residue position
with the glycan receptor. It was demonstrated previously that an
analogous mutation in the prototypic 1918 pandemic (A/South
Carolina/1/1918 or SC18) HA resulted in shifting its glycan
receptor-binding from high specificity for a2-6 sialylated glycans to
a mixed binding to both a2-6 (albeit at a lower affinity than wild-
type HA) and a2-3 sialylated glycans [27,28].
To investigate the effect of D222G mutation on glycan-receptor
binding properties of CA/04 virus, we analyzed the binding of
both wild-type and mutant virus in a dose-dependent fashion to
representative a2-3 and a2-6 sialylated glycans on a glycan array
platform (Figure 1). Our analysis showed that D222G mutation
resulted in a modest reduction in the binding avidity to a2-6
sialylated glycans (69SLN and, to a lesser extent, 69SLN-LN) in
comparison with the wild-type virus. The notable difference in
glycan-binding properties was the substantial increase in binding
of D222G mutant virus to a2-3 sialylated glycans (relative to its
a2-6 binding) compared with that of wild-type virus. These results
with CA/04 virus are consistent with previous observations
demonstrating an increase in a2-3 binding of other 2009 H1N1
viruses carrying the D222G mutation [24].
Effect of D222G mutation on pathogenesis and
respiratory droplet transmission
A recent study demonstrated that the introduction of D222G
in a 2009 H1N1 virus did not alter the pathogenicity or
transmissibility of a 2009 H1N1 isolate A/Netherlands/602/09
in ferrets [22]. However, the use of a parental strain which already
possesses a highly transmissible phenotype may limit the ability to
identify additional molecular changes which could confer
enhanced transmissibility [29]. In contrast, the 2009 H1N1 CA/
04 virus, which exhibits reduced transmissibility in the ferret
model compared with seasonal H1N1 viruses, and previously
enabled us to identify an HA mutation which conferred efficient
transmission by respiratory droplets in ferrets was used in this
study to more stringently assess the impact of D222G on virus
transmission [30,31].
Ferrets inoculated with the D222G virus exhibited similar
clinical signs as CA/04 wild-type virus and a reverse-genetics
derived CA/04 virus, with ferrets exhibiting transient weight loss
(mean maximum weight loss of 11.3% on day 6–7 p.i.) and fever
(mean maximum fever 1.9uC over baseline day 2 p.i.) before
returning to baseline levels [30,31]. D222G virus-infected ferrets
further exhibited a mild, transient lymphopenia (22% decrease in
circulating lymphocytes on day 3 p.i.) which was comparable to
ferrets infected with other 2009 H1N1 viruses [32]. D222G virus
was detected in the ferret upper respiratory tract (6.760.2 log10
PFU/ml nasal turbinates) and the lower respiratory tract (6.360.6
log10 PFU/g lung tissue) at similar titers as 2009 H1N1 wild-type
viruses day 3 p.i. [22]. Moreover, the D222G mutant virus was
detected in the intestinal tract of 1/3 ferrets day 3 p.i. (2.29 log10
PFU/ml), and in rectal swabs collected on days 1 and 3 p.i. in 2/3
ferrets (average titer 1.460.2 log10 PFU/ml), comparable to other
2009 H1N1 isolates [31].
To evaluate the transmissibility of D222G virus by respiratory
droplets, three ferrets were inoculated with 106 PFU of virus.
Approximately 24 hours p.i., inoculated-contact pairs were
established by placing naı¨ve ferrets in each of three adjacent
modified cages with a perforated side wall, allowing air exchange
between ferrets in the absence of direct or indirect contact. Nasal
washes (NW) were collected on alternate days p.i. or post-contact
(p.c.) for virus titration. Detection of infectious virus in NW of
contact ferrets and seroconversion of contact ferrets were
considered evidence of virus transmission. Consistent with the
experimental transmission data obtained with wild type 2009
H1N1 viruses [31], CA/04 virus did not spread by respiratory
droplet to every contact ferret; infectious virus was detected in the
nasal washes of two of three contact ferrets (Figure 2A) [30].
D222G virus replicated efficiently in the upper respiratory tract of
inoculated ferrets, reaching peak mean titers of 7.560.2 log10
PFU/ml day 1 p.i., significantly higher than CA/04 virus at this
time (p,0.03) [30]. Similar to CA/04 virus, D222G mutant virus
was detected in NW of two of three contact ferrets, with virus titers
.7 log10 PFU/ml on day 3 p.c. (Figure 2B). While detectable virus
was not observed in NW of the third contact ferret, all three
contact ferrets seroconverted to homologous virus by day 20 p.i.
(HI titer range 320–640). This pattern of D222G virus
transmission by respiratory droplets was confirmed in a duplicate
experiment that resulted in virus detection in NW in two of three
contact ferrets and seroconversion of all contact ferrets (data not
shown). Ferret lung and NW samples from inoculated and contact
animals that were harvested were sequenced to confirm the
mutation. All samples yielded the expected mutant sequence;
reversion of the mutation (222G to 222D) was not observed.
Enhanced virulence of D222G virus in mice by the
intranasal but not intraocular route
To determine whether the D222G mutation conferred
heightened virulence of a 2009 H1N1 virus in a mouse model,
we inoculated mice i.n. with 105 PFU of either CA/04 or D222G
virus. Mice inoculated with D222G virus by the intranasal route
exhibited greater weight loss than CA/04 virus-inoculated mice;
one mouse from the D222G group was euthanatized on day 11 p.i.
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due to excessive weight loss (Table 1). However, neither virus
exhibited .50% lethality in mice when inoculated at this dose.
While both viruses replicated efficiently in the lungs of mice on
days 3 and 6 p.i., D222G virus replicated to a significantly higher
mean titer compared with CA/04 virus at day 6 p.i. (p,0.05).
Virus was found infrequently and at low titer in the nose and
intestines of mice from both groups on day 3 p.i. only (Table 1 and
data not shown). Similar titers of virus in the lung and sporadic
detection of virus in intestinal tissue with these viruses was
observed with numerous other 2009 H1N1 viruses in this model
[33].
A recent report indicated that the presence of D222G enhanced
the ability of a 2009 H1N1 virus to cause ocular disease in mice,
with virus detected in the eye of one mouse following intranasal
inoculation [22]. We did not observe extrapulmonary spread of
virus to the eyes of mice following intranasal inoculation with
either CA/04 or D222G virus, and ocular disease was not
observed during visual examination of mice during the course of
infection (data not shown). However, to better assess the ability of
the D222G mutation to cause ocular disease in mice, we
inoculated mice by the ocular route with both viruses. The right
eye of each mouse was lightly scarified with a 2-mm corneal
trephine blade, and 105 PFU of each virus in a 5 ml volume was
deposited onto the corneal epithelial surface and massaged into the
eye with the eyelid. Mice inoculated by the ocular route with either
virus did not exhibit substantial morbidity, and virus was not
detected in the eye, nose, intestine, or lung on day 3 or 6 p.i. (data
not shown). These results indicate that CA/04 virus is not well
suited to infect mice by the ocular route, and the presence of
D222G does not confer an ocular tropism in this model.
D222G mutation does not alter 2009 H1N1 virus tropism
in human respiratory and ocular cells
Previous studies have demonstrated that select influenza viruses
which do not demonstrate an ocular tropism in mice nonetheless
are capable of high-titer replication in human ocular cells [34]. To
Figure 1. Dose-dependent glycan array-binding of CA/04 D222G virus. Dose-dependent binding of CA/04 D222G (A) or wild-type CA/04 (B)
virus to representative a2-3 and a2-6 sialylated glycans on the glycan array. The y-axis shows percentage of maximum binding signal intensities. In
both cases saturation binding signals were observed at viral titers of 128 HAUs. The chemical description of glycans is provided in Table S1. The
69SLN-LN glycan is representative of the predominant glycan motifs expressed in the human upper respiratory tract.
doi:10.1371/journal.pone.0025091.g001
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rule out the possibility that the D222G mutation confers an ocular
tropism not observed in our murine model, we compared the
ability of CA/04 and D222G viruses to replicate in primary
human corneal epithelial cells (HCEpiC), which predominantly
express a2-3 linked sialic acids [34]. HCEpiC were infected at a
MOI of 0.01 and supernatants were collected at indicated times
p.i. to quantify infectious virus (Figure 3, open symbols). Both CA/
04 and D222G viruses were detected at low levels (,3 log10 PFU/
ml) through 72 hrs p.i. in this cell type. In contrast, both viruses
replicated efficiently in the human bronchial epithelial cell line
Figure 2. Respiratory droplet transmissibility of D222G virus. Three ferrets were inoculated with 106 PFU of reverse-genetics CA/04
(published previously in [30]) (A) or D222G (B) virus. All ferrets were housed individually in specialized cages that permit exchange of respiratory
droplets, but prevent direct or indirect contact between inoculated-contact animal pairs. A naı¨ve ferret was placed in an adjacent cage to an
inoculated ferret 24 hrs p.i. Viral replication was determined by titration of nasal washes collected on alternate days from inoculated (left bars) and
contact (right bars) ferrets. The limit of virus detection was 10 PFU/ml.
doi:10.1371/journal.pone.0025091.g002
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Calu-3 (Figure 3, closed symbols). Similar to a previous study, we
observed a slight delay in D222G virus replication in Calu-3 cells
at 24 hrs p.i., with titers of D222G virus being 10-fold lower than
CA/04 virus (p,0.02) [22]. However, at 48 and 72 hrs p.i.,
D222G virus replicated to significantly higher titer than CA/04
virus in the human respiratory cells (p,0.0005). Primary human
lung blood microvascular endothelial cells (HMVEC-LBI) express
a greater proportion of a2-3 linked sialic acids compared with
Calu-3 cells (H. Zeng, personal communication), but did not
support efficient replication of either CA/04 or D222G viruses.
Taken together, these findings indicate that the D222G mutation
confers enhanced replication in respiratory epithelial cells but does
not alter the ocular tropism of 2009 H1N1 virus.
Discussion
The detection of D222G among severe and fatal cases of human
infection has resulted in analyses to determine if this mutation
represents the first virulence marker associated with 2009 H1N1
pandemic viruses. Previous studies have investigated the effect of
D222G HA mutation on glycan-binding using binding assays such
as red blood cell agglutination and binding to glycan arrays at
saturating viral titers [22,24]. While these assays serve as good
screening tools to understand the extent of a2-3 or a2-6 binding,
they were not designed to understand relative binding-avidity of
the virus in a dose-dependent fashion. In this study, we used a
dose-dependent direct binding assay, mammalian models, and
human in vitro cultures to evaluate the relative contribution of this
mutation to the virulence of a 2009 H1N1 virus. We demonstrate
that a single D222G amino acid change augments binding to a2-3
linked sialic acids and results in higher overall titers of infectious
virus in human airway cells and mouse lungs compared with wild-
type virus. However, this change is not sufficient to enhance
disease or confer efficient transmission of this virus by respiratory
droplets in the ferret model and does not augment the ability to
replicate in a2-3-rich human or murine ocular tissue.
The consequence of the D222G mutation on viral replication
kinetics has been assessed previously in several relevant cell lines.
Compared with wild-type virus, a D222G-bearing virus replicated
to higher titers in human alveolar basal epithelial A549 cells,
although generally similar kinetics between D222G and wild-type
viruses were observed in the human placental cell line JEG-3 and
MDCK cells [20,21,22]. We observed lower viral titers of D222G
virus compared with CA/04 virus 24 hrs p.i. in Calu-3 cells, in
agreement with a previous study using MDCK cells which also
noted reduced viral titers with a virus bearing this mutation at this
time p.i. [22]; however, significantly higher titers of D222G virus
compared with wild-type virus were detected in Calu-3 cells at 48
and 72 hrs p.i. Interestingly, similar viral replication kinetics were
observed in our murine model, with comparable titers between
CA/04 and D222G viruses in the lungs of mice on day 3 p.i. but
higher D222G virus titers in this tissue at day 6 p.i. However, the
enhanced ability of D222G virus to bind to a2-3 linked sialic acids
did not confer the ability to replicate efficiently in respiratory
endothelial cells. Along with these previously published studies,
our data suggests that the presence of D222G can enhance viral
Table 1. Pathogenesis of CA/04 and 222G viruses following intranasal inoculation in mice.
Viral titerb
Virus % wt lossa Survival Lung (D3) Nose (D3) Intestine (D3) Lung (D6)
CA/04 15.8% (4) 5/5 6.060.3 (3/3) 2.1 (1/3) 1.5 (1/3) 5.160.5 (2/3)
D222G 22.1% (10) 4/5 6.260.1 (3/3) 1.760.6 (2/3) 1.7 (1/3) 5.960.1 (3/3)c
aMean maximum percent weight loss (5 mice per group) following inoculation with 105 PFU. Day post-inoculation (p.i.) indicated in parentheses.
bVirus endpoint titers are expressed as the mean log10 PFU/ml plus standard deviation. Day 3 (D3) and Day 6 (D6) p.i. are shown. Numbers of mice with detectable virus
included in the mean are indicated in parentheses.
cp,0.05 compared with CA/04 virus by Student’s t test.
doi:10.1371/journal.pone.0025091.t001
Figure 3. Replication kinetics of CA/04 and D222G viruses in human ocular and respiratory cells. Calu-3 (circles), HMVEC-LBI (triangles),
or HCEpiC (squares) cells were infected at a MOI of 0.01 with the indicated viruses (CA/4, closed symbols; D222G, open symbols). Culture supernatants
were removed at indicated times p.i., and titers were determined for infectious virus by standard plaque assay. The limit of virus detection was
10 PFU/ml. The mean from triplicate independent cultures per virus 6 standard deviation is shown.
doi:10.1371/journal.pone.0025091.g003
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replication in some cell types, but this contribution is modest and is
only apparent at later stages of infection.
Previous studies have demonstrated that, in general, 2009
H1N1 viruses are not highly pathogenic in mice [33,35]. However,
these viruses are capable of acquiring a lethal phenotype in mice
following acquisition of key mutations, one of which is D222G
[20,36]. A previous study found that the D222G mutation on the
CA/04 background conferred greater morbidity, mortality, and
heightened virus replication in the lungs of mice compared with a
wild-type virus, which is in agreement with our results [19]. An
additional study performed a similar assessment of virulence with
this mutation, but the use of a parental strain which is lethal for
mice may have masked subtle differences conferred by the D222G
mutation [22]. In the ferret model, the D222G mutation on the
CA/04 background did not confer enhanced virulence, in
accordance with previous results [22]. Thus, results in the ferret
model have not supported a role of D222G in enhancing 2009
H1N1 virus virulence. Extrapulmonary spread of virus to the
intestinal tract was detected following infection with both CA/04
and D222G viruses, a feature shared by numerous wild-type 2009
H1N1 viruses [31]. However, D222G virus failed to spread to
other tissues following infection in either mice or ferrets. The
enhanced replication and morbidity in mice, but not ferrets
following D222G virus infection, is consistent with augmented
binding to a2-3 sialylated glycans and the known predominance of
a2-3 sialic acids in the mouse model [37].
Unlike seasonal influenza viruses which exhibit efficient
transmission by respiratory droplets in the ferret model, our
studies have shown that most 2009 H1N1 viruses and triple-
reassortant swine H1N1 viruses possess reduced transmissibility by
this route [29,31,32,38]. The 2009 H1N1 viruses consistently
transmitted to two of three ferrets, as measured by virus detection
in nasal washes (Figure 2A and [31]). Although a single base-pair
change (leading to the I216K mutation) in CA/04 HA can lead to
efficient transmission in ferrets [30], we found that the D222G
mutation did not appear to significantly enhance or diminish
transmission (4 of 6 naı¨ve contact ferrets had detectable virus in
nasal washes) of the 2009 H1N1 virus. The enhanced transmission
observed with the HA (Ile219RLys) may be due, at least in part,
to its increased human receptor-(a2-6) binding affinity (particularly
to the 69SLN-LN glycan) by several-fold in comparison with wild-
type [30]. However, differences in receptor binding specificity
between CA/04 and D222G did not preclude efficient replication
of both viruses in ferret nasal wash samples. The inability of
D222G virus to confer efficient respiratory droplet transmission
may be related to the findings that this particular HA mutation
does not substantially improve a2-6 binding avidity of the virus. In
fact, molecular epidemiologic studies revealed that the majority of
2009 H1N1 viruses circulating during the pandemic did not bear
the D222G mutation, further suggesting that this mutation is not a
determinant of virus transmissibility [11,39].
While rare, reports of conjunctivitis following 2009 H1N1 virus
infection have been documented [17,40,41]. Studies have also
shown that select 2009 H1N1 viruses are capable of replicating in
human ocular cell types, albeit to lower titer than avian influenza
viruses [42]. However, it appears that 2009 H1N1 viruses, similar
to seasonal influenza viruses, are not well-suited to use the eye as a
portal of entry, as ocular infection of mice with these viruses fails to
result in a productive virus infection [33]. In the present study, the
presence of D222G did not confer the ability of this virus to infect
mice by the ocular route or the ability to replicate more efficiently
compared with wild-type CA/04 virus in human corneal epithelial
cells. The detection of macroscopic ocular symptoms in mice
infected with a virus bearing the D222G mutation in a previous
study may be due to strain-specific differences between parental
viruses used or laboratory-specific conditions, but does not appear
to be a universal property of 2009 H1N1 viruses possessing this
mutation [22]. Nonetheless, the lack of productive replication of
D222G virus in human ocular cells indicates that the enhanced
cell tropism present with this virus, observed in the ability to bind
both ciliated and non-ciliated cells in HTBE cell cultures, does not
translate to all cell types [24].
The relatively rapid emergence of D222G during serial passage
in mice, cells, or eggs indicates the ability of 2009 H1N1 viruses to
acquire this mutation under the right conditions, and the lack of
reversion observed in this study suggests that this mutation is stably
maintained. [20,24,36,43]. In support of this, numerous studies
have reported that the mutation arises during course of human
influenza (2009 H1N1) infection [11,12,13]. Further study is needed
to better understand other molecular markers of the 2009 H1N1
virus that are known to be associated with severe disease and the
role of these mutations on the virulence of other virus subtypes. This
work underscores the importance of studying the contribution of
virulence markers such as D222G on parental strains that do not
themselves possess heightened virulence to avoid masking subtle
differences which, while minor, nonetheless result in a detectable
increase in virus pathogenicity in mammals. These results taken
together with those of others demonstrate that it can be difficult to
unequivocally demonstrate experimentally that a particular muta-
tion is associated with enhanced severity since different animal
models yield different results. In addition, subtle differences in
viruses, experimental conditions and other factors may result in
somewhat different results from different laboratories; nevertheless,
the association of the D222G mutation with more severe human
infections highlights the need to continue research in this area.
Materials and Methods
Rescue of recombinant influenza A viruses
The eight reverse-genetics plasmids used for the rescue of
recombinant influenza A/California/04/09 (CA/04) virus were
constructed as described previously [30,44,45]. The mutation
from Asp to Gly at HA position 222 was achieved by altering the
position 222 codons from GAT(D) to GGT(G) using a Stratagene
QuikChange II Site-Directed Mutagenesis kit (Agilent Technolo-
gies, Santa Clara, CA) per manufacturer’s instructions on the CA/
04 HA plasmid template.
CA/04 and 222G viruses were rescued as described previously
[30]. Briefly, 293T cells were transfected with the eight CA/04
plasmids and co-cultured with MDCK cells 12 hrs post-
transfection. Rescued viruses were isolated by plaque purifica-
tion on MDCK cells. Coding sequences of plasmids and rescued
viruses were confirmed by automated sequencing performed at
the Influenza Sequence Activity, Influenza Division, Centers for
Disease Control and Prevention. Experiments with CA/04 and
222G viruses were conducted under biosafety level 3 contain-
ment with enhancements, in accordance with guidelines of
the WHO. (https://www.who.int/csr/resources/publications/
swineflu/Laboratorybioriskmanagement.pdf).
Dose dependent direct binding of CA/04 D222G virus by
glycan array
A streptavidin plate array comprising representative biotiny-
lated a2R3 and a2R6 sialylated glycans as described previously
[28,30] (Table S1) was used for the analysis. 39SLN, 39SLN-LN,
39SLN-LN-LN are representative avian receptors. 69SLN and
69SLN-LN are representative human receptors. The biotinylated
glycans were obtained from the Consortium of Functional
D222G HA Mutation on Viral Binding and Virulence
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25091
Glycomics through their resource request program. Streptavidin-
coated High Binding Capacity Pierce 384-well Microplates
(Pierce, Rockford, IL) were loaded to the full capacity of each
well by incubating the well with 50 ml of 2.4 mM of biotinylated
glycans overnight at 4uC. Excess glycans were removed through
extensive washing with PBS. The viruses were diluted based on
hemagglutinating units (HAU, obtained using 0.5% turkey
erythrocytes) with 1X PBS+1% BSA. 50 ml of the diluted virus
was added to each of the glycan – coated wells and incubated
overnight at 4uC. This was followed by three washes with 1X
PBST (1X PBS+0.1% Tween-20) and three washes with 1X PBS.
Each of the wells was blocked with 1X PBS+1% BSA for 2 h at
4uC. The wells were incubated with primary antibody (ferret anti –
CA/04 antisera; 1:500 diluted in 1X PBS+1% BSA) and
incubated for 5 h at 4uC. This was followed by three washes with
1X PBST and three washes with 1X PBS. Finally the wells were
incubated with the secondary antibody (goat anti – ferret HRP
conjugated antibody from Abcam; 1:500 diluted in 1X PBS+1%
BSA). The wells were washed with 1X PBST and 1X PBS as
before. The binding signals were determined based on the HRP
activity using the Amplex Red Peroxidase Assay (Invitrogen)
according to the manufacturer’s instructions. The assays were
done in triplicate and appropriate negative controls were included.
Ferret pathogenesis and transmission experiments
Male Fitch ferrets (Triple F Farms, Sayre, PA), 8–10 months of
age and serologically negative by hemagglutination inhibition (HI)
assay for currently circulating influenza viruses, were used in this
study. Ferrets were housed for the duration of the experiment in
cages within a Duo-Flow Bioclean environmental enclosure (Lab
Products, Seaford, DE). The pathogenesis of each virus was assessed
following intranasal (i.n.) inoculation of 106 PFU of virus in a 1 ml
volume, a dose reported to consistently infect ferrets with human or
avian influenza viruses, was determined as previously described
[46,47]. Ferret hematologic and blood chemistry analyses were
performed as previously described [32]. Transmission of virus by
respiratory droplets was performed as previously described [38].
Nasal washes were collected from ferrets every other day for at least
9 days post-inoculation (p.i.) or contact (p.c.) and titrated by
standard plaque assay using MDCK cells. Post-exposure serum was
collected from virus-inoculated (15–19 days p.i.) and contact (18–21
days p.c.) ferrets and tested for H1-specific antibodies against
homologous virus by HI assay using 0.5% turkey erythrocytes [48].
Mouse pathogenesis and ocular tropism experiments
Female BALB/c mice (Charles River Laboratories, Wilmington,
MA), 8–12 weeks of age, were inoculated i.n. with 105 PFU of CA/
04 or D222G virus in a 50 ml volume as previously described [33].
Ocular infection of mice with CA/04 and D222G viruses was
performed as previously described using 105 PFU in a 5 ml volume
[34]. Five mice per group were monitored daily for 14 days p.i. for
morbidity, as measured by body weight, and mortality. Any mouse
which lost .25% of its pre-inoculation body weight was
euthanatized. Three mice per group were euthanatized on days 3
and 6 p.i., and eye, nose, intestine, and lung tissues were collected to
determine replication and systemic spread of virus. Tissues were
homogenized in 1 ml of cold PBS, and clarified homogenates were
titrated by standard plaque assay. Statistical significance for these
and all experiments was determined using Student’s t test.
In vitro replication kinetics
The bronchial epithelial cell line Calu-3 (ATCC, Manassas, VA)
was cultured on membrane inserts and infected apically as
previously described [49]. Primary human corneal epithelial cells
(HCEpiC) were obtained from ScienCell (San Diego, CA) at
passage 1 and were prepared for virus infection as described
previously [34]. Primary human lung blood microvascular
endothelial cells (HMVEC-LBI) were obtained from Lonza
(Walkersville, MD) and cultured with Endothelial Cell Basal
Medium-2 (Lonza) (Zeng et al, in preparation). Virus was added to
Calu-3, HCEpiC, or HMVEC-LBI monolayers at a multiplicity of
infection (MOI) of 0.01 for one hour before washing. Cell type
specific serum-free media was added to all wells with the addition
of 300 mg/L N-p-tosyl-L-phenylalanine chloromethyl ketone-
treated (TPCK) trypsin (Sigma-Aldrich, St. Louis, MO) in cultures
using primary human cells. Aliquots of culture supernatant taken
post-infection (p.i.) from triplicate cultures were immediately
frozen at 280uC until titrated for the presence of infectious virus
by standard plaque assay.
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